Clinuvel is “cheap” because the market has very little faith in their ability to deliver. This is not complicated. N=6 pilot trials take at least 2 years to conclude safety ( which no one was seriously concerned about anyway). Nothing gets taken further. Vitiligo, possibly but it has been 14 years getting to this point with a couple of bullshit trials in the interim. Cuv107 is still uncertain.
I did a little preliminary reading on afa and PD. A lot of the rationale is related to mc1r in the SN. Centrally delivered afa has shown a decline in alpha syn In mice. However, afa cannot act centrally as it does not cross the bbb. It is hypothesized that it may exert an effect by influencing T regs, but the alpha syn effect is unproven.
i also noted that palatin has commenced a weight loss trial with MT2, n=60.
Ann: CLINUVEL Newsletter III - June 2024, page-20
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.74 |
Change
-0.240(1.60%) |
Mkt cap ! $738.1M | |||
| Open | High | Low | Value | Volume |
| $14.99 | $15.02 | $14.61 | $887.1K | 59.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 88 | $14.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.74 | 6 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |